{
    "medicine_id": "b5bb61a62bd455ef109cc877ca8c6ec0bb6161d4",
    "platform_id": "DB08885",
    "metadata": {
        "name": "Eylea 40 mg ml Injection solution",
        "composition": "40 mg ml Aflibercept",
        "clinical_particulars": {
            "therapeutic_indications": "The opthalmic agent is used for the treatment of neovascular wet age related mascular degeneration AMD and macular edema following central retinal vein occulsion CRVO The systemic injection known as ziv aflibercept in combination with 5 fluorouracil leucovorin irinotecan FOLFIRI is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin",
            "contraindications": {
                "disease": "For all intravitreal VEGF inhibitors there is increased risk of stroke and myocardial infarction An increase in intraocular pressure may also occur When used intravenously most common adverse reactions were leukopenia diarrhea neutropenia proteinuria AST increased stomatitis fatigue thrombocytopenia ALT increased hypertension weight decreased decreased appetite epistaxis abdominal pain dysphonia serum creatinine increased and headache",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Compared to other anti VEGF drugs like bevacizumab and ranibizumab aflibercept has a higher binding affinity to VEGF A Kd 0 5 pM",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}